© 2020 MJH Life Sciences and HCPLive. All rights reserved.
July 23, 2020
The Patient Controller will join a growing list of Abbott digital care products aimed at streamlining the therapeutic experience.
July 22, 2020
The approval represents the second approved treatment of the conditions associated with narcolepsy patients at least 7 years old.
July 21, 2020
Symptom provocation did not meaningfully alter the diagnostic sensitivity and specificity that is relative to more easily obtained pretests symptom ratings.
Both telemedicine and face-to-face therapy resulted in improved daytime function.
July 17, 2020
New research finds a 13% higher mortality rate for every 5% reduction in REM sleep.
July 09, 2020
The best results came from second-stage therapies, which produced significant increases in remission and response rates.
Shorter nighttime sleep duration and later bedtime at 3.5 years old age were significantly associated with borderline personality disorder symptoms.
July 08, 2020
Those who received the agent in EMERGE reported a significant slowing of decline on measures of cognition and function such as memory, orientation, and language, as well as for activities of daily living.
Tests for N-methyl-Daspartate receptor, myelin oligodendrocyte glycoprotein, and aquaporin-4 autoantibodies had negative results in all patients.
The presence of anxiety symptoms moderated most alterations in emotional processing observed following sleep restriction.